Abstract:BACKGROUND & OBJECTIVE:Axillary lymph node dissection (ALND) is routinely performed during surgery for breast cancer, but whether ALND could increase survival rate of early stage breast cancer patients remains controversial. Recently, replacing ALND with sentinel lymph node (SLN) biopsy has became a hotspot in breast cancer research. This study aimed to evaluate the reliability and accuracy of SLN biopsy for early stage breast cancer, and to discover the significance of multiple step section level cytokeratin immunohistochemistry in identifying micrometastatic disease.METHODS:SLN biopsy was performed on 121 patients with T1 or T2 breast cancer: methylene blue-labeling was used in 38 patients (methylene blue group), double-labeling of (99m)Tc sulfur colloid and methylene blue was used in 83 patients (combination group). Lymphoscintigraphy and hand-hold gamma detector were used to localize SLNs before operation. All SLNs and ALND lymph nodes were pathologically examined. The tumor-negative SLNs were cut at three levels, and detected by immunohistochemistry.RESULTS:Success rates were 81.6% in methylene blue group, and 95.2% in combination group; accurate detection rates of axillary lymph nodes were 93.5% in methylene blue group, and 97.5% in combination group. SLNs were found in 19 patients (23%) by lymphoscintigraphy, and 76 patients (92%) by hand-hold gamma detector, respectively (P=0.04). A total of 194 negative SLNs, detected by routine pathologic examination, were re-examined by multiple step section level cytokeratin immunohistochemistry; micrometastatic diseases were identified in 21 SLNs of 13 patients. The accuracy rate of combined examinations was 98.7%, and the false-negative rate was 3.2%.CONCLUSIONS:The axillary node status can be predicted by SLN biopsy; double-staining is better than methylene blue-labeling. The role of lymphoscintigraphy in SLN biopsy needs further explore. Multiple step section level cytokeratin immunohistochemistry can improve detection rate of micrometastatic diseases.

Progress of sentinel lymph node tracer agents in breast cancer

Different Criteria for Radioactive Sentinel Lymph Nodes Has Different Impact on Sentinel Node Biopsy in Breast Cancer Patients

Clinical Study of Sentinel Lymph Node Biopsy in Colon Cancer

Tracers′ Clinical Application Status in the Sentinel Lymph Node Biopsy of Breast Cancer

Current studies and evaluations of sentinel lymph node biopsy for breast cancer

[Detection of Sentinel Lymph Node in Patients with Breast Cancer].

Research Progress of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy for Breast Cancer

Update on Sentinel Lymph Node Methods and Pathology in Breast Cancer

Application of a Carbon Nanoparticle Suspension for Sentinel Lymph Node Mapping in Patients with Early Breast Cancer: a Retrospective Cohort Study.

Progress in clinical researches of sentinel lymph node biopsy in breast cancer patients with neoad-juvant chemotherapy

Sentinel Lymph Node Biopsy in Breast Cancer: Current Status and Recent Progress

Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Patients with Breast Cancer

[Lymphoscintigraphy in Sentinel Lymph Node Biopsy of Breast Cancer].

Sentinel lymph node biopsy (SLNB) vs. axillary lymph node dissection (ALND) in the current surgical treatment of early stage breast cancer

[Detection of Sentinel Lymph Node in Patients with Early Stage Breast Cancer].

Mammary sentinel lymphoscintigraphy in breast cancer

The Detection and Clinical Significance of Sentinel Lymph Node Biopsy in Breast Cancer

Precise Intraoperative Sentinel Lymph Node Biopsies Guided By Lymphatic Drainage In Breast Cancer

Research progress of axillary management approach for 1-2 sentinel lymph node positive early stage breast cancer patients

Intra-operative Radionuclide Lymphatic Mapping in Sentinel Lymph Node Biopsy of Breast Cancer

Feasibility of subareolar injection technique for breast cancer sentinel lymph node biopsy